In 2005, the Food and Drug Administration's approval of BiDil for use only in self-identified African Americans brought to the fore the longstanding debate about the use of race and ethnicity in medical research and practice. While this issue has received considerable attention in science and social science literature, thus far there has been little consideration about the legal and regulatory implications of "race-based medicine." This paper seeks to fill this gap by advocating the use of Institutional Review Boards (IRBs) in balancing the social and medical implications of race-based research. To assist them in this role, I propose a model to guide IRB approval of clinical trials based on the role of race or ethnicity in the study design. That is, whether a study includes racial and ethnic minorities (1) with no specific analyses of racial or ethnic variability (race-inclusive research); (2) for the purpose of studying potential differences between racial or ethnic groups (race-targeted research) or (3) for the purpose of studying specific racial or ethnic groups (race-exclusive research). Compliance with such a model could significantly improve the process for developing any future race-based drugs.

Item Type:	Refereed Article
Research Division:	Law and Legal Studies
Research Group:	Public law
Research Field:	Public law not elsewhere classified
Objective Division:	Law, Politics and Community Services
Objective Group:	Justice and the law
Objective Field:	Justice and the law not elsewhere classified
UTAS Author:	Eckstein, LG (Dr Lisa Eckstein)
ID Code:	91185
Year Published:	2011
Web of Science® Times Cited:	3
Deposited By:	Faculty of Law
Deposited On:	2014-05-09
Last Modified:	2014-05-09
Downloads:	0